ClinConnect ClinConnect Logo
Search / Trial NCT00000910

A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of May 11, 2025

Completed

Keywords

Pregnancy Anti Hiv Agents

ClinConnect Summary

The population served at affiliated ACTG sites has not been officially described. Anecdotal evidence, however, has surfaced regarding the characteristics of HIV-infected pregnant women and the current standard of care during pregnancy. This chart abstraction study is designed to define, more accurately, the pertinent characteristics and general numbers of women in these trials.

In this medical chart abstraction study, pertinent information is collected on all HIV-infected pregnant women and their infants who receive primary or consultative care at PACTG 367 study sites. Part A profiles all...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria
  • A patient may be eligible for this study if she:
  • Is an HIV-positive woman.
  • Is receiving care at a study site during the study period or her infant is receiving care at a study site and whose delivery information is available.
  • Had a baby on or after January 1, 1998.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Boston, Massachusetts, United States

Newark, New Jersey, United States

Patients applied

0 patients applied

Trial Officials

Ruth Tuomala

Study Chair

Renee Samelson

Study Chair

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials